ANDA 204902, held by Pharmobedient. Dapiprazole Hydrochloride.
As of Nov 16, 2026, ANDA 204902 (Dapiprazole Hydrochloride), held by Pharmobedient, was first approved by FDA on May 29, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 29, 2019 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dapiprazole Hydrochloride0.5% ยท solution/drops;ophthalmic | Dapiprazole Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters